Tau immunotherapy
The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
1. An antibody comprising a heavy chain comprising a mature heavy chain variable region having the amino acid sequence of SEQ ID NO:35 linked to heavy constant region having the sequence of SEQ ID NO:29 with or without the C-terminal lysine and a mature light chain variable region having the amino sequence of SEQ ID NO:36 linked to a light chain constant region having the amino acid sequence of SEQ ID NO:32.
2. A nucleic acid encoding the heavy and light chains of an antibody as described in claim 1 .
3. A host cell comprising the nucleic acid of claim 2 .
4. The host cell of claim 3 , wherein the cell is a CHO or Sp2/0 cell.
5. A method of producing an antibody comprising, culturing the host cell of claim 3 , wherein the antibody is expressed from the nucleic acid.
6. A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable carrier.
7. A method of treating or effecting prophylaxis of Alzheimer's disease comprising administering an effective regime of an antibody as defined in claim 1 and thereby treating or effecting prophylaxis of Alzheimer's disease.
8. The method of claim 7 , wherein the patient is an ApoE4 carrier.
9. A method of treating or effecting prophylaxis of a disease associated with tau comprising administering an effective regime of an antibody as defined in claim 1 and thereby treating or effecting prophylaxis of the disease.
10. The method of claim 9 , wherein the disease is a neurological disease.
11. Nucleic acids encoding the heavy and light chains of an antibody of claim 1 .
12. A host cell comprising the nucleic acids of claim 11 .
13. The host cell of claim 12 , wherein the cell is a CHO or Sp2/0 cell.
14. A method of producing an antibody comprising, culturing the host cell of claim 12 , wherein the antibody is expressed from the nucleic acids.